Art

J-GLOBAL ID：201702249483478735   Reference number：17A1541860

HOW WILL MOLECULAR-TARGETED THERAPIES AFFECT SURGICAL TREATMENT?

分子標的療法は外科治療をどう変えるか 7.大腸癌

Author (4)： HASEGAWA HIROSHI (神戸大 外科 食道胃腸外科) ,  YAMASHITA KIMIHIRO (神戸大 外科 食道胃腸外科) ,  MATSUDA TAKERU (神戸大 外科 食道胃腸外科) ,  KAKEJI YOSHIHIRO (神戸大 外科 食道胃腸外科)
Material： 日本外科学会雑誌  (Journal of Japan Surgical Society)
Volume： 118  Issue： 6  Page： 639-645  Publication year： Nov. 01, 2017 
JST Material Number： Z0009B  ISSN： 0301-4894  Document type： Article
Article type： 解説  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： *colorectal neoplasm ,...
Semi thesaurus term： Bevacizumab ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1541860&from=J-GLOBAL&jstjournalNo=Z0009B") }}

JST classification (1)： Tumors(=neoplasms)of digestive system  (GH04000D)

Reference (20)：

• Stintzing S, Modest DP, Rossius L, et al.: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3) : a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol, 17 : 1426-1434, 2016.
• Venock AP, Niedzwiecki D, Lenz HJ, et al.: CALGB/SWOG 80405 : Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol, 32 : 5s(suppl; abstr LBA3), 2014.
• Saltz LB, Clarke S, Díaz-Rubio E, et al. : Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer : a randomized phase III study. J Clin Oncol, 26 : 2013-2019, 2008.
• Van Cutsem E, Köhne CH, Hitre E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 360 :1408-1417, 2009.
• Douillard JY, Siena S, Cassidy J, et al. : Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer : the PRIME study. J Clin Oncol, 28 : 4697-4705, 2010.

Terms in the title (3)： 分子標的療法 ,  外科治療 ,  大腸癌